BJDX Bluejay Diagnostics, Inc.
Price Chart
Executive Summary
Bluejay Diagnostics entered into a manufacturing services agreement with Argonaut Manufacturing Services to establish U.S.-based production of its IL-6 test cartridges for the Symphony platform, moving away from overseas manufacturing. The agreement covers tech transfer, formulation, fill/finish, and QC release testing, with an estimated 14-18 week delivery timeline from purchase order receipt. No financial terms were disclosed, and the Symphony System remains an investigational device without FDA clearance.
Actionable Insight
This is a routine supply-chain partnership for a pre-revenue, pre-FDA-clearance company. No financial terms were disclosed, so there is no immediate revenue or cost read-through. Monitor for future purchase orders under the agreement and for progress in the SYMON clinical program (SYMON-II pivotal study) which would support a 510(k) submission.
Key Facts
- Agreement signed May 27, 2026 with Argonaut Manufacturing Services for IL-6 cartridge manufacturing
- Services include tech transfer, formulation, filling, finishing, QC testing, and distribution
- Estimated 14-18 week delivery from purchase order receipt
- Symphony System is an investigational device — no FDA clearance yet
- No financial terms (deal value, pricing, minimum commitments) disclosed in the filing
- Company has $2M market cap and 0% analyst bullish consensus
Financial Impact
No financial terms disclosed in the filing; deal value, pricing, and minimum purchase commitments are not specified
Risk Factors
- Symphony System has no FDA clearance — commercial manufacturing is contingent on regulatory approval
- No minimum purchase commitments disclosed — Argonaut may not generate meaningful revenue for Bluejay
- Company has $2M market cap with 0% analyst bullish consensus — high risk of capital constraints
- Historical performance shows prior bullish call on this ticker lost -8.05% at T+20
Market Snapshot
Documents Analyzed
This report is based on 7 press releases from GlobeNewswire.
| Document | Accession Number |
|---|---|
| 8-K Filing (BJDX) — Batch item 1 | 0001213900-26-063767 |
| Document: ea0293118-8k_bluejay.htm | 0001213900-26-063767 |
| Document: ea029311801ex99-1.htm | press-3304952 |
| Document: 0001213900-26-063767-index-headers.html | press-3304952 |
| Document: 0001213900-26-063767-index.html | press-3304952 |
| Document: 0001213900-26-063767.txt | press-3304952 |
| PRESS-RELEASE Data (Synthetic) | press-3304952 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 9, 2026
7d ago
|
8-K
| $4.49 $4.74 | ▲ +5.57% | ▲ +3.87% | $4.54 (+1.11%) |
|
Jun 8, 2026
8d ago
|
8-K
| $4.50 $4.49 | ▲ +0.22% | ▼ −1.35% | $4.54 (−0.89%) |
|
Jun 6, 2026
11d ago
|
Press Release
| $5.23 $4.50 | ▲ +13.96% | ▲ +13.66% | $4.54 (+13.19%) |
|
Jun 2, 2026
14d ago
|
Press Release
| $4.34 $4.51 | ▼ −3.92% | ▼ −4.61% | $4.54 (−4.61%) |
|
Jun 2, 2026
14d ago
|
PRESS-RELEASE / 8-K
| $4.34 $4.51 | ▲ +3.92% | ▲ +4.61% | $4.54 (+4.61%) |
|
May 18, 2026
29d ago
|
Insider Cluster
| $1.71 $1.78 | ▲ +3.98% | ▲ +2.94% | $4.54 (+165.50%) |
|
May 7, 2026
5w ago
|
8-K
| $1.72 $1.76 | ▲ +2.33% | ▲ +2.09% | $4.54 (+163.95%) |
|
May 7, 2026
5w ago
|
Press Release
| $1.72 $1.76 | ▲ +2.33% | ▲ +2.09% | $4.54 (+163.95%) |
|
Apr 7, 2026
10w ago
|
8-K
| $2.05 $2.05 | · 0.00% | ▼ −2.54% | $4.54 (+121.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access